Henrik Luessen is taking over as Chief Business Officer at Promethera Biosciences SA, Belgian developer of cell-based meds. He will be responsible for identifying and executing strategic corporate development initiatives and licensing agreements.
Lund-based probiotics expert Probi AB has appointed Jörn Andreas as new CFO. He will replace Niklas Brandt, who in turn will take over responsibility for IT infrastructure and IR as CIO.
Pfizers Cyprus Business Manager Kyriakos Mikellis has been re-elected for the next two years as president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA).
Starting in May, Matthias Baumann will be new Chief Medical Officer of immunotherapy specialist Mologen AG. His primary goal will be preparing Mologens DNA cancer therapy lefitolimod for market launch.
Ex-Novartis Senior VP Judith Klimovsky has joined Copenhagen-based Genmab as Executive Vice President and Chief Development Officer. The appointment is meant to pave the way for the antibody specialist to grow into a global biotech company.
One Nucleus, the Cambridge-based not-for-profit membership organisation for international life science and healthcare companies, announced the appointment of Linda Summerton as a Director. Summerton is Chief Executive of Immodulon and a Senior Partner with TranScrip Partners.
University of Warwick spin-out Medherant Ltd has appointed Ken Cunningham as its chair right in time for the companys move into the clinical development of its novel transdermal drug delivery patch technology. Cunningham is already Chairman of Abzena as well as Non-Executive Director of Verona Pharma plc.
Applied Photophysics, a provider of systems for the biophysical characterisation of biomolecules, has appointed Louise Madden as Chief Executive Officer. She joined Applied Photophysics in March 2014 as commercial director, before being promoted to chief operating officer in 2015.
Developer of treatments for neuromuscular and neuro-ophthalmological diseases Santhera Pharmaceuticals has hired Kristina Sjöblom Nygren as Chief Medical Officer and Head of Development.
Belgian ViroVet NV, which develops vaccines and antiviral drug for livestock, has named George Gunn as the newest member of its board of directors. Until early 2015, Gunn was CEO of Novartis Animal Health and a member of the global executive committee of Novartis.